Table of Contents
The term "light therapy" is used loosely in both clinical and consumer contexts to describe treatments ranging from medically supervised UV phototherapy to consumer red light panels sold online. Phototherapy typically refers to the use of ultraviolet or visible light to treat specific medical conditions, while photobiomodulation, also known as red light therapy, uses visible red and near-infrared wavelengths aimed at cellular and tissue-level effects like inflammation and healing. Understanding the meaningful distinctions between categories of light-based medicine is essential for anyone navigating this space to realize its powerful benefits.
What is Phototherapy?
Phototherapy, in its clinical definition, refers to the therapeutic use of ultraviolet or visible light — typically delivered at controlled doses — to treat specific medical conditions. The mechanism is primarily photochemical: UV phototherapy produces photochemical effects that can alter cellular proliferation and immune signaling, including induction of apoptosis in activated T cells and modulation of inflammatory pathways.
Phototherapy is generally considered a medical treatment. Standard delivery systems usually require trained staff, calibrated equipment, and individualized dosing protocols. Conditions treated with phototherapy under medical supervision include:
Psoriasis (plaque, guttate, and palmoplantar types)
Neonatal jaundice (blue light phototherapy)
Seasonal affective disorder (bright white light therapy)
What Is Photobiomodulation (Red Light Therapy)?
Photobiomodulation (PBM) - also called low-level laser therapy (LLLT) or red light therapy — refers to the use of red and near-infrared light (typically 630-1,070 nm) to stimulate cellular function. The mechanism is distinct from UV phototherapy: rather than changing cell DNA or triggering vitamin D pathways, PBM works by stimulating mitochondrial cytochrome c oxidase, enhancing ATP production, reducing oxidative stress, and modulating inflammation.
The biological effects of PBM occur through photochemical and cellular signaling pathways distinct from those of UV phototherapy. This distinction has important regulatory and safety implications: PBM devices do not cause sunburn, DNA damage, or acute tissue effects, making home use by consumers more practical and generally safer — though optimal dosing remains a clinical consideration.
Clinical PBM applications include wound healing, pain management, sports recovery, hair loss treatment, and emerging neurological applications. Consumer red light panels and devices have proliferated in this space, though the quality and clinical validation of consumer products varies significantly.
Clinical vs. Home Light Therapy: What's the Difference?
The line between clinical and home use in light therapy is drawn primarily by risk profile,dosing complexity, and device safety features:
Narrowband UVB phototherapy often requires clinical supervision because the margin between a therapeutic dose and a harmful one is narrow, calibration of UVB bulbs decays over time with lamp age, and the consequences of overdose (severe burns, blistering, long-term skin damage) require professional management.
Broadband UVB home devices exist but they are an older form of UVB phototherapy, less preferred by clinicians, and carry similar risks to narrowband phototherapy.
Solius has recently developed a new category of FDA cleared home UVB light therapy that is available without a prescription. Advanced safety features including a precise UVB spectrum and personalized dosing using a built-in skin sensor allow this technology to offer UVB light therapy safely in the home.
Red and near-infrared photobiomodulation devices are generally considered safe for home use, though optimal dosing parameters are still being refined.
Bright white light therapy for SAD is commonly administered at home using UV-filtered light boxes.
What Conditions Does Narrowband UVB Treat?
The most widely used form of UV phototherapy today is narrowband UVB (NB-UVB), which emits light with a peak at 311-313 nm — a tightly focused slice of the UVB spectrum. This specific wavelength range was identified in research from the 1980s as the therapeutically optimal band for psoriasis treatment: effective enough to drive the desired biological response while excluding shorter UVB wavelengths that carry higher erythema risk.
Medical Applications of Narrowband UVB
Narrowband UVB is widely used and guideline-supported for several inflammatory and pigmentary skin disorders. Its therapeutic effect on psoriasis involves inhibiting the proliferation of keratinocytes (the skin cells that overproduce in psoriasis), inducing apoptosis in activated T cells, and modulating inflammatory cytokines.
For vitiligo, NB-UVB stimulates melanocyte migration and differentiation at the borders of depigmented patches, with repigmentation rates comparable to topical corticosteroids. For atopic dermatitis, it reduces Th2-driven inflammation in the skin.
The effectiveness of NB-UVB is well-established by decades of clinical trials, and it is endorsed by major dermatological bodies worldwide including the American Academy of Dermatology, the British Association of Dermatologists, and the European Dermatology Forum.
Why Traditional Narrowband UVB Phototherapy Typically Requires Clinical Oversight
Despite its proven efficacy, traditional narrowband UVB phototherapy typically remains confined to clinical settings or prescription-required home use with clinical oversight for several important reasons:
Dose calibration is critical and technically demanding. Therapeutic doses are measured in millijoules per square centimeter (mJ/cm²), and the starting dose is typically based on the patient's Fitzpatrick skin type. Dosing increases incrementally (known as titration) over weeks of treatment until the optimal dose is reached. Without calibrated equipment and trained staff, overdosing is easy and the risks of overdosing are potentially severe.
Lamp output decays over time. NB-UVB lamps often use UVB bulbs that lose irradiance with use, and devices must be regularly tested and calibrated to maintain accurate dosing. This requires specialized equipment.
Treatment requires careful monitoring for side effects, including burns, blistering, and the rare but real long-term risk of cumulative UV-related skin damage.
The equipment is large, expensive, and designed for clinical throughput — not personal or home use.
The UVA Contamination Problem
A critically underappreciated concern with narrowband UVB devices — including clinical systems — is UVA contamination. No commercial NB-UVB lamp emits exclusively at 311-313 nm. Real-world NB-UVB fluorescent lamps emit a broader spectrum that includes significant UVA output, typically in the 340-400 nm range.
UVA contributes to oxidative stress in the skin, collagen degradation, and - crucially - is recognized as a co-carcinogen in melanoma development. Long-term accumulation of UVA exposure from repeated phototherapy sessions adds to lifetime UVA burden. For patients undergoing hundreds of treatments for chronic conditions, this represents a meaningful consideration that clinical teams must weigh against therapeutic benefit.
This UVA contamination is inherent to the lamp technology used in most NB-UVB systems and is not correctable without fundamentally different light source technology. Filters can reduce but not eliminate UVA output from fluorescent NB-UVB sources. Recently, specialized UVB LEDs selected for their narrow spectrum have started becoming available in some UVB light therapy technologies.
Challenges with Over-The-Counter UVB Light Therapy
A growing market of home UVB devices — ranging from sunlamps marketed for vitamin D production to home phototherapy units for psoriasis — has emerged alongside rising awareness of vitamin D deficiency and light therapy's health benefits.
While some home UVB products offer genuine value, they share fundamental challenges that make consistent, safe, and personalized UVB delivery difficult to achieve without appropriate technology, safety features, and regulatory oversight.
The Problem of Unregulated Devices
The appeal of home UVB light therapy is understandable. But the proliferation of unregulated devices has outpaced the regulatory frameworks designed to protect consumers from them.
Regulatory clearance — whether FDA clearance in the United States or a Health Canada medical device license — is not a bureaucratic formality. It is required for light therapy devices in the UVB light spectrum and is the pathway by which a device's safety claims are independently verified, its output characterized, its labeling reviewed, and its risk profile assessed against a defined intended use. A device without that clearance has made none of those demonstrations. For a category where the margin between a therapeutic dose and a harmful one can be measured in seconds of exposure, that distinction matters.
The consequences are not hypothetical. Health Canada has issued safety notices against multiple unlicensed UVB products that can be bought online without a prescription — including the Chroma-D Light UV Lamp, the Dermahealer UVB Light Therapy Lamp, and Mitolux UV Sunlamps — citing health risks associated with uncontrolled UV output and lack of proper licensing. These are not fringe products. They are actively marketed for the same vitamin D and wellness applications that legitimate, regulated devices address. The difference is that unlicensed devices carry no assurance of output accuracy, dose consistency, or user safety.
The Problem of Output Control
Home UVB lamps typically emit a fixed output that varies with lamp age, ambient temperature, warm-up time, and power supply variation. Unlike clinical phototherapy systems — which are regularly calibrated with radiometers and have dose-tracking software — most home devices offer no reliable measurement of the actual UV irradiance delivered to the skin at any given session.
A lamp that delivered a specific dose when new may deliver significantly less six months later as the bulb ages, without any visible indication to the user. This means that someone attempting to maintain a consistent dose will progressively receive less UVB over time - and someone starting with a calibrated dose may unknowingly cause burns if they begin with a fresh lamp without adjusting exposure time.
Why UVB Dose Varies With Distance From the Source — and Why That Matters
UVB irradiance is not uniform across the emitting surface of a lamp or panel, nor is it uniform across the surface of skin at varying distances from the source. UVB irradiance varies with distance from the source, as well as with source geometry, beam characteristics, and positioning. Therefore, inconsistent treatment distance can substantially alter the delivered UV dose.
Consumer devices rarely account for this, and users who position themselves inconsistently — varying their distance, angle, or proximity — will receive highly variable doses at each session which could lead to ineffective therapy, at best, or risk of erythema and burns, at worst.
Clinical phototherapy cabinets address this through precise, enclosed geometry that positions the patient at a consistent distance from arrays of calibrated lamps, ensuring uniform delivery across the treatment area. This engineering is absent from most consumer products.
Why One Exposure Time Can't Work for Everyone
Perhaps the most significant limitation of consumer UVB devices is the absence of personalized dosing. The optimal UVB dose for any individual depends on:
Skin tone: Fair-skinned individuals need much lower exposures than darker-skinned individuals, thus requiring shorter sessions to produce vitamin D without burning.
Genetic variation: Polymorphisms in vitamin D receptor genes, CYP enzymes involved in vitamin D metabolism, and melanin synthesis genes all influence how an individual responds to UVB and how efficiently they convert it to vitamin D.
History of sun exposure: Individuals with significant recent UV exposure have higher baseline melanization and may need a higher UVB dose than those who are UV-naive and more sensitive.
Body surface area being treated: The amount of vitamin D produced and the risk of burning both depend directly on how much skin is exposed.
Most home UVB devices provide none of this context. A single recommended exposure time — whether printed on the box or derived from a generic table — cannot safely or effectively serve the full range of individuals who might use the device.
Darker Skin Tones and UVB Therapy: An Underserved Clinical Gap
Standard UVB exposure protocols were largely developed in clinical settings with predominantly fair-skinned populations. People with Fitzpatrick skin types V and VI — which include individuals of African, South Asian, and some East Asian and Indigenous heritage — have significantly higher baseline melanin density. Melanin is a natural UV absorber, which means people with darker skin need substantially more UV energy to produce the same biological effect.
For vitamin D synthesis, individuals with Fitzpatrick type VI may require up to 8 times more UVB exposure than someone with type I or II to generate equivalent previtamin D3. For phototherapy, the same principle applies to dosing. NB-UVB dosing generally requires adjustment for skin phototype or individual erythema response, and assessment and optimization of dosing can be more challenging in darker skin.
This creates both a clinical gap and an equity issue. The clinical gap: The research base for NB-UVB phototherapy, and the dosing tables derived from it, underrepresents types V and VI. Many clinical protocols still default to Fitzpatrick-based dosing tables that were not derived from diverse cohorts. The result is that darker-skinned patients are more likely to receive suboptimal initial doses, require more sessions to achieve therapeutic benefit, and be assessed using frameworks not built for their skin biology.
The equity dimension compounds the clinical one. Darker-skinned individuals already face higher rates of vitamin D insufficiency because of the melanin-UV absorption relationship — especially at higher latitudes where UVB is already scarce. They are simultaneously harder to dose correctly in phototherapy and underrepresented in the clinical data that informs those protocols because consumer UVB devices — already imprecise — are even less suited to their needs. A fixed-dose device that does not account for differences in skin response may deliver an inappropriate dose for some users with darker skin.
Addressing this gap requires dedicated research into dosing protocols for types V and VI, development of devices capable of precision calibration across the full Fitzpatrick range, and greater inclusion of diverse skin types in both clinical trials and the normative data that guides phototherapy practice.
The promise of precision UVB light therapy lies in combining the known science of UVB biology with real-time sensing, individual biometric input, and intelligent dose calculation - delivering the biological benefits of sunlight at the right dose, for the right person, at the right time. This is the engineering challenge at the frontier of consumer photobiology.
As light-based therapies become more common, understanding the differences between them matters more than ever. While terms like phototherapy, photobiomodulation, and red light therapy are often used interchangeably, they rely on different wavelengths, work through different biological mechanisms, and are designed for different goals. The distinctions between these therapies and the devices that deliver them have direct consequences for whether a user receives a therapeutic dose or a subtherapeutic one, whether a device helps or harms, and whether the benefits of light-based medicine reach the people who need them most.
Editorial Notes
This article is intended for general informational purposes and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your supplement regimen or sun exposure practices, particularly if you have a medical condition or take medications that may affect vitamin D metabolism.
